Onkologie. 2015:9(5):235-238

Recurrence of malignant gyneacological tumors

Martina Kubecová, Klaudia Regináčová
Radioterapeutická a onkologická klinika 3. LF UK a FNKV, Praha

Malignant gyneacological tumors recurrence rate depends on many factors. Most significant ones are primary tumor volume, its biological

properties, and radicality of performed therapy. Relapses treatment is always more and more difficult and possibility of recovery depends

not only on size of local relapse, its deposition, and patient‘s condition, but especially on previously performed therapy. Treatment plan

has to be created for every patient individually, in which surgery, radiotherapy, chemotherapy, and most frequently a combination of all

these methods are considered. Our research suggests that relatively high percentage of gyneacological relapses are curable.

Keywords: recurrence of malignant gynaecological tumors, surgery, external beam radiotherapy, brachytherapy, chemotherapy

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubecová M, Regináčová K. Recurrence of malignant gyneacological tumors. Onkologie. 2015;9(5):235-238.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Creutzberg CL, van Puten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patiens with stage-1 endometrial carcinoma: multicentre randomised trial.PORTEC Study Group. Post Operative Radiation Therapy in Endometrial carcinoma. Lancet. 2000; 355(9213): 1404-1411. Go to original source...
    2. Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the Randomized PORTEC-2 Trial. J Clin Oncol 2009; 27(21): 3547-3556. Go to original source... Go to PubMed...
    3. Šlampa P, Petera J, Kubecová M, et all. Malignant tumour of the uterine corpus. Radiation oncology, Galen-Karolinum, Prague; 2007: 265-267.
    4. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24(1): 36-44. Go to original source... Go to PubMed...
    5. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol 1989; 28(4): 561-566. Go to original source...
    6. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163. Go to original source... Go to PubMed...
    7. Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003; 90: 390-396. Go to original source... Go to PubMed...
    8. Hoskins P, Vergote I, Cervantes A, et al. Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel. J Natl Cancer Inst 2010; 102: 1547-1556. Go to original source... Go to PubMed...
    9. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338. Go to original source... Go to PubMed...
    10. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012; 107(4): 588-591. Go to original source... Go to PubMed...
    11. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28: 4162-4169. Go to original source... Go to PubMed...
    12. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: A randomized, double-blinded, pla-cebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29: Abstract LBA 5007. Go to original source...
    13. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32(13): 1302-1308. Go to original source... Go to PubMed...
    14. Knutson, K.L; Karyampudi, L.; Lamichhane, P. et al. Targeted immune therapy of ovarian cancer. Cancer metastasis reviews, Dec 30, 2014, ISSN: 0167-7659, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24637997&dopt=Abstract

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.